The quarter modestly cleared the market bar. Adjusted diluted EPS was $1.31 versus a published consensus of roughly $1.28, while sales reached $12.593 billion versus approximately $12.48 billion expected.
| Metric | 2Q26 | Comparison | Read-through |
|---|---|---|---|
| Net sales | $12.593B | $11.142B prior year | Reported growth of 13.0%; comparable growth only 4.8% (Financial Highlights; Comparable Revenue table) |
| Adjusted diluted EPS | $1.31 | $1.26 prior year; ~$1.28 consensus | 4.0% year-over-year growth and a modest beat (Financial Highlights) |
| GAAP diluted EPS | $0.53 | $1.01 prior year | Heavily distorted by $1.362B of specified after-tax charges (Financial Highlights; Specified Items) |
| Medical Devices comparable sales | — | — | 8.4% growth, led by electrophysiology and diabetes care (Sales — Medical Devices) |
| Diagnostics comparable sales | — | — | 2.9% growth excluding the Exact Sciences acquisition (Sales — Diagnostics) |
| Nutrition comparable sales | — | — | Down 3.6% (Sales — Nutrition) |
The headline sales growth overstates the underlying acceleration. The 13.0% reported increase includes the Exact Sciences acquisition and foreign-exchange effects; comparable sales grew 4.8%. Medical Devices remained the cleanest operating engine at 8.4% comparable growth, but Nutrition declined 3.6% and Diagnostics grew only 2.9% excluding acquired Exact Sciences revenue (Comparable Revenue table; Sales — Medical Devices; Sales — Nutrition; Sales — Diagnostics).
Earnings quality was better than GAAP, but cost pressure remains visible. Adjusted EPS rose 4.0%, yet total operating costs increased 19.9% against 13.0% reported sales growth. The gap reflects higher amortization, acquisition-related costs, legal reserves and other specified items; excluding those charges, earnings improved, but the filing does not show broad operating leverage (Income Statement; Specified Items).
Management raised the full-year earnings range, making the net read better than the small quarterly beat alone. Full-year adjusted EPS guidance increased to $5.45–$5.60 from $5.38–$5.58, while comparable sales growth guidance was reaffirmed at 6.5%–7.5%. That is a modest upgrade rather than a major reset: the earnings range moved higher, but the sales outlook did not, leaving the result narrowly ahead of expectations rather than a broad fundamental reacceleration.
Read the original 8-K on SEC EDGAR ↗